Category: 138801-92-0

Dewanji, Abhishek; van Dalsen, Leendert; Rossi-Ashton, James A.; Gasson, Eloise; Crisenza, Giacomo E. M.; Procter, David J. published an article in 2021, the title of the article was A general arene C-H functionalization strategy via electron donor-acceptor complex photoactivation.Formula: C10H7NO2 And the article contains the following content:

The photoactivation of electron donor-acceptor (EDA) complexes has emerged as a sustainable, selective and versatile strategy for the generation of radical species. However, when it comes to aryl radical formation, this strategy remains hamstrung by the electronic properties of the aromatic radical precursors and electron-deficient aryl halide acceptors are required. This has prevented the implementation of a general synthetic platform for aryl radical formation. Our study introduces triarylsulfonium salts as acceptors in photoactive EDA-complexes, used in combination with catalytic amounts of newly-designed amine donors. The sulfonium salt label renders inconsequential the electronic features of the aryl radical precursor and, more importantly, it is installed regioselectively in native aromatic compounds by C-H sulfenylation. Using this general, site-selective aromatic C-H functionalization approach, we have developed metal free protocols for the alkylation and cyanation of arenes, and showcased their application in both the synthesis and the late-stage modification of pharmaceuticals and agrochems. The experimental process involved the reaction of 4-Oxochroman-6-carbonitrile(cas: 138801-92-0).Formula: C10H7NO2

The Article related to arene carbon hydrogen functionalization donor acceptor complex photoactivation, alkylation cyanation triarylsulfonium salt silane intermediate radical mechanism, General Organic Chemistry: Synthetic Methods and other aspects.Formula: C10H7NO2

Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts

On May 22, 2008, Ohlmeyer, Michael; Bohnstedt, Adolph; Kingsbury, Celia; Ho, Koc-Kan; Quintero, Jorge published a patent.Computed Properties of 138801-92-0 The title of the patent was Preparation of 7-substituted purine derivatives as immunosuppressants. And the patent contained the following:

Purinone derivatives of formula I [Q1, Q2 = (substituted) CH, N; Q3 = CH, N; R1-R3 = H, alkyl; R4 = alkyl, heterocyclyl, aryl, heteroaryl, etc.; R5 = alkyl, heterocyclyl, etc.; n = 0-3] are prepared for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. Thus, II was prepared, and inhibited IL-2 induced IFN-γ production by >40% at 30 mg/kg in mice. The experimental process involved the reaction of 4-Oxochroman-6-carbonitrile(cas: 138801-92-0).Computed Properties of 138801-92-0

The Article related to purinone derivative preparation immunosuppressant, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Computed Properties of 138801-92-0

Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts

On November 30, 1991, Buckle, Derek R.; Eggleston, Drake S.; Houge-Frydrych, Catherine S. V.; Pinto, Ivan L.; Readshaw, Simon A.; Smith, David G.; Webster, Richard A. B. published an article.Application of 138801-92-0 The title of the article was Conformational and steric modifications of the pyran ring of the potassium channel activator cromakalim. And the article contained the following:

The syntheses of analogs of the novel smooth muscle relaxant cromakalim, (I), in which the C-2 Me groups have been successively replaced by hydrogen, are described and the relative stereochem. of the two corresponding, isomeric monomethyl compounds, unambiguously assigned by 1H NMR spectroscopic techniques. Single-crystal x-ray anal. of the 2伪-monomethyl compound showed that it existed in a distorted half-chair conformation in the solid state and confirmed the relative orientation of the C-2, C-3 and C-4 substituents. The 2尾-Me isomer appeared to exist in a single conformation in solution, with the pyran ring adopting a half-chair conformation and with all the substituents in this ring occupying a pseudoequatorial position. The solution behavior of the 2伪-Me isomer is more complex, however, although it seems likely to exist as a distorted half-chair conformer similar to that found in the solid state. The syntheses of two related benzoxepines are also described. All compounds were less potent than cromakalim itself, which is consistent with the view that di-Me substitution at C-2 is essential for optimal activity. The experimental process involved the reaction of 4-Oxochroman-6-carbonitrile(cas: 138801-92-0).Application of 138801-92-0

The Article related to cromakalim analog preparation conformation, Heterocyclic Compounds (One Hetero Atom): Benzopyrans (Including Coumarins, Isocoumarins, Chromones, Benzopyrones, Dibenzopyrans, and Other Arenopyrans) and other aspects.Application of 138801-92-0

Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts

On January 24, 2013, Wang, Xueqing; Meyer, Michael; Yao, Betty; Guo, Tao; Wei, Guo Pingrobert; Wang, Lijuan Jane published a patent.Name: 4-Oxochroman-6-carbonitrile The title of the patent was Preparation of 1,6-naphthyridine derivatives as chemokine receptor antagonists. And the patent contained the following:

The invention relates to 1,6-naphthyridine derivatives of formula I and pharmaceutically acceptable salts, solvates and prodrugs thereof as chemokine receptor antagonists; their preparation and use in the treatment of pain. Compounds of formula I wherein X1 is CR1 and N; X2 is CR2 and N; X3 is CR3 and N; R1, R2 and R3 are independently H, CN, halo, etc.; G1 is NR4R5, substituted pyridinyl, etc.; R4 is H,(halo)alkyl, alkoxyalkyl, etc.; R5 is (un)substituted heterocyclyl, Ph, naphthyl, cycloalkyl, etc.; and pharmaceutically acceptable salts, solvates and prodrugs thereof, are claimed. Example compound II 鈥?succinate was prepared by a multistep procedure (procedure given). All the invention compounds were evaluated for their chemokine receptor antagonistic activity. From the assay, it was determined that example compound II 鈥?succinate exhibited Kb value ranged from 0.003 渭M to 0.006 渭M. The experimental process involved the reaction of 4-Oxochroman-6-carbonitrile(cas: 138801-92-0).Name: 4-Oxochroman-6-carbonitrile

The Article related to naphthyridine preparation chemokine receptor antagonist treatment pain, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Name: 4-Oxochroman-6-carbonitrile

Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts

On November 30, 1991, Buckle, Derek R.; Eggleston, Drake S.; Houge-Frydrych, Catherine S. V.; Pinto, Ivan L.; Readshaw, Simon A.; Smith, David G.; Webster, Richard A. B. published an article.Application of 138801-92-0 The title of the article was Conformational and steric modifications of the pyran ring of the potassium channel activator cromakalim. And the article contained the following:

The syntheses of analogs of the novel smooth muscle relaxant cromakalim, (I), in which the C-2 Me groups have been successively replaced by hydrogen, are described and the relative stereochem. of the two corresponding, isomeric monomethyl compounds, unambiguously assigned by 1H NMR spectroscopic techniques. Single-crystal x-ray anal. of the 2伪-monomethyl compound showed that it existed in a distorted half-chair conformation in the solid state and confirmed the relative orientation of the C-2, C-3 and C-4 substituents. The 2尾-Me isomer appeared to exist in a single conformation in solution, with the pyran ring adopting a half-chair conformation and with all the substituents in this ring occupying a pseudoequatorial position. The solution behavior of the 2伪-Me isomer is more complex, however, although it seems likely to exist as a distorted half-chair conformer similar to that found in the solid state. The syntheses of two related benzoxepines are also described. All compounds were less potent than cromakalim itself, which is consistent with the view that di-Me substitution at C-2 is essential for optimal activity. The experimental process involved the reaction of 4-Oxochroman-6-carbonitrile(cas: 138801-92-0).Application of 138801-92-0

The Article related to cromakalim analog preparation conformation, Heterocyclic Compounds (One Hetero Atom): Benzopyrans (Including Coumarins, Isocoumarins, Chromones, Benzopyrones, Dibenzopyrans, and Other Arenopyrans) and other aspects.Application of 138801-92-0

Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts

On January 24, 2013, Wang, Xueqing; Meyer, Michael; Yao, Betty; Guo, Tao; Wei, Guo Pingrobert; Wang, Lijuan Jane published a patent.Name: 4-Oxochroman-6-carbonitrile The title of the patent was Preparation of 1,6-naphthyridine derivatives as chemokine receptor antagonists. And the patent contained the following:

The invention relates to 1,6-naphthyridine derivatives of formula I and pharmaceutically acceptable salts, solvates and prodrugs thereof as chemokine receptor antagonists; their preparation and use in the treatment of pain. Compounds of formula I wherein X1 is CR1 and N; X2 is CR2 and N; X3 is CR3 and N; R1, R2 and R3 are independently H, CN, halo, etc.; G1 is NR4R5, substituted pyridinyl, etc.; R4 is H,(halo)alkyl, alkoxyalkyl, etc.; R5 is (un)substituted heterocyclyl, Ph, naphthyl, cycloalkyl, etc.; and pharmaceutically acceptable salts, solvates and prodrugs thereof, are claimed. Example compound II 鈥?succinate was prepared by a multistep procedure (procedure given). All the invention compounds were evaluated for their chemokine receptor antagonistic activity. From the assay, it was determined that example compound II 鈥?succinate exhibited Kb value ranged from 0.003 渭M to 0.006 渭M. The experimental process involved the reaction of 4-Oxochroman-6-carbonitrile(cas: 138801-92-0).Name: 4-Oxochroman-6-carbonitrile

The Article related to naphthyridine preparation chemokine receptor antagonist treatment pain, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Name: 4-Oxochroman-6-carbonitrile

Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts

On November 20, 2008, Ohlmeyer, Michael J.; Bohnstedt, Adolph C.; Kingsbury, Celia; Ho, Koc-Kan; Quintero, Jorge Gabriel; You, Ming; Park, Haengsoon; Lu, Yingchun published a patent.Synthetic Route of 138801-92-0 The title of the patent was Preparation of purinones and imidazopyridinones as JAK3 kinase inhibitors useful as immunosuppressants. And the patent contained the following:

Title compounds e.g. [I; Q = CX1, N; X1 = H, cyano, halo, haloalkyl haloalkoxy; R4 = (substituted) aryl], were prepared Thus, (R)-4-(2,4-dimethoxybenzylamino)-3-[4-(6-fluorochroman-4-ylamino)-5-nitropyrimidin-2-ylamino]benzonitrile was stirred with Na2S2O4 and NaHCO3 in THF/H2O/MeOH to give (R)-4-(2,4-dimethoxybenzylamino)-3-[4-(6-fluorochroman-4-ylamino)-5-aminopyrimidin-2-ylamino]benzonitrile. The latter was microwaved with p-TsOH and (MeO)3CH in MeOH at 150° for 5 min. to give 3-[9-((R)-6-fluorochroman-4-yl)-9H-purin-2-yl]-3H-benzo[d]imidazole-5-carbonitrile. The latter and other title compounds showed JAK3 inhibitory activity with IC50 <100 nM. The experimental process involved the reaction of 4-Oxochroman-6-carbonitrile(cas: 138801-92-0).Synthetic Route of 138801-92-0

The Article related to purinone imidazopyridinone preparation jak3 kinase inhibitor, cancer inflammation psoriasis transplant rejection psoriasis treatment purinone preparation, chromanylpurinylbenzimidazole preparation autoimmune disease treatment and other aspects.Synthetic Route of 138801-92-0

Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts

On May 22, 2008, Ohlmeyer, Michael J.; Bohnstedt, Adolph; Kingsbury, Celia; Ho, Koc-Kan; Quintero, Jorge published a patent.Synthetic Route of 138801-92-0 The title of the patent was Preparation of 7-substituted purine derivatives as inhibitors of tyrosine kinase Jak3 for immunosuppression. And the patent contained the following:

The present invention provides novel purinone and related derivatives [I; Q1, Q2 = independently CX1, CX2, or N wherein Q1 and Q2 are not both N; Q3 = N or CH; X1, X2 = independently H, C1-6 alkyl, cyano, halo, halo-C1-6 alkyl, HO, C1-6 alkoxy, halo-C1-6 alkoxy, or NO2; R1 = H, C1-6 alkyl; y = 0 or an integer of 1-3 ; R2 and R3 are selected independently for each occurrence of (CR2R3) from H and C1-6 alkyl; R4 = each (un)substituted alkyl, heterocyclyl, aryl, or heteroaryl; R5 = alkyl, (un)substituted heterocyclyl, or C1-C6 alkyl wherein (a) one or two CH2 is replaced by a group chosen from NH and N(alkyl); (b) one or two CH2 is replaced by O; (c) one or two CH2 is replaced by (C:O); (d) two CH2 are replaced by CH:CH or CC; or (e) any chem. stable combination of (a), (b) (c) and (d); and wherein from zero to three hydrogens is replaced by a substituent chosen from: (a) halogen, hydroxy, cyano, lower alkylsulfonyl, lower alkylsulfonyloxy, amino, lower alkylamino, di(lower alkyl)amino, alkoxyamino, sulfonylamino, acylamino, arylamino, lower alkoxy; (b) (un)substituted heterocyclyl; (c) (un)substituted Ph; and (d) (un)substituted heteroaryl]. These compounds are inhibitors of Jak3 kinase and useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease, hematol. malignancy, and transplant rejection. Thus, a solution of 20 mg 3-[9-((R)-6,8-difluorochroman-4-yl)-8-oxo-8,9-dihydro-7H-purin-2-yl]-3H-benzo[d]imidazole-5-carbonitrile in 2 mL MeCN was treated with 90 mg Me bromoacetate and 100 mg 2-tert-butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphorine on polystyrene (2.2 mmol base/g) and the mixture was stirred at room temperature 48 h, and then filtered to give, after concentration of the filtrate in vacuo, Me 2-[2-(6-cyano-1H-benzo[d]imidazol-1-yl)-9-((R)-6,8-difluorochroman-4-yl)-8-oxo-8,9-dihydropurin-7-yl]acetate (II). The compounds I including II showed IC50 of 101 nM-1 μM against tyrosine kinase Jak3. The experimental process involved the reaction of 4-Oxochroman-6-carbonitrile(cas: 138801-92-0).Synthetic Route of 138801-92-0

The Article related to purine derivative preparation immunosuppressant, autoimmune disease inflammatory disease prevention treatment purine derivative preparation, mast cell mediated disease prevention treatment purine derivative preparation, hematol malignancy transplant rejection prevention treatment purine derivative preparation, tyrosine kinase jak3 inhibitor purine derivative and other aspects.Synthetic Route of 138801-92-0

Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts